HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

4- ((1- butyl- 3- phenylureido)methyl)- N- hydroxybenzamide

inhibits HDAC6; structure in first source

Also Known As:

nexturastat A

Networked: 5 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133

Experts

1.	Hadley, Melissa: 2 articles (01/2020 - 10/2017)
2.	Villagra, Alejandro: 2 articles (01/2020 - 10/2017)
3.	Balakrishnan, Preethi B: 1 article (01/2020)
4.	Bollard, Catherine M: 1 article (01/2020)
5.	Cano-Mejia, Juliana: 1 article (01/2020)
6.	Fernandes, Rohan: 1 article (01/2020)
7.	Ledezma, Debbie K: 1 article (01/2020)
8.	Sweeney, Elizabeth E: 1 article (01/2020)
9.	Anh, Duong T: 1 article (01/2019)
10.	Barinka, Cyril: 1 article (01/2019)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2019 - "The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma." 01/01/2019 - "Two new series of N-hydroxybenzamides and N-hydroxypropenamides analogues (4a-j, 6a-j) designed based on the structural features of nexturastat A, AR-42, and PXD-101, were synthesized and evaluated for HDAC inhibitory potency as well as cytotoxicity against three human cancer cell lines (SW620 (colorectal adenocarcinoma), PC3 (prostate adenocarcinoma), and NCI-H23 (adenocarcinoma, non-small cell lung cancer). "
2.	Multiple Myeloma 01/01/2019 - "The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma." 01/01/2019 - "We herein report our new generation of multifunctional HDAC6 degraders by tethering selective HDAC6 inhibitor Nexturastat A with CRBN ligand that can synergize with HDAC6 degradation for the antiproliferation of multiple myeloma (MM). "
3.	Melanoma (Melanoma, Malignant) 01/17/2020 - "Indocyanine Green-Nexturastat A-PLGA Nanoparticles Combine Photothermal and Epigenetic Therapy for Melanoma." 10/12/2017 - "In our effort to identify potent and isoform-selective histone deacetylase (HDAC) inhibitors as a therapeutic approach to melanoma, a series of new HDAC6 inhibitors based on the nexturastat A scaffold were prepared. "
4.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/01/2019 - "Two new series of N-hydroxybenzamides and N-hydroxypropenamides analogues (4a-j, 6a-j) designed based on the structural features of nexturastat A, AR-42, and PXD-101, were synthesized and evaluated for HDAC inhibitory potency as well as cytotoxicity against three human cancer cell lines (SW620 (colorectal adenocarcinoma), PC3 (prostate adenocarcinoma), and NCI-H23 (adenocarcinoma, non-small cell lung cancer). "
5.	Adenocarcinoma 01/01/2019 - "Two new series of N-hydroxybenzamides and N-hydroxypropenamides analogues (4a-j, 6a-j) designed based on the structural features of nexturastat A, AR-42, and PXD-101, were synthesized and evaluated for HDAC inhibitory potency as well as cytotoxicity against three human cancer cell lines (SW620 (colorectal adenocarcinoma), PC3 (prostate adenocarcinoma), and NCI-H23 (adenocarcinoma, non-small cell lung cancer). "

Related Drugs and Biologics

1.	Histone Deacetylase Inhibitors
2.	Protein Isoforms (Isoforms)
3.	Ligands
4.	Indocyanine Green (Cardio-Green)
5.	Histone Deacetylases (Histone Deacetylase)

Related Therapies and Procedures

1.	Therapeutics